Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 359 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Zyban Clear all

Conditions: Restless Legs Syndrome
Interventions: Bupropion, Placebo; Drug
Lead sponsor: East Tennessee State University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Johnson City, Tennessee

Conditions: Advanced Solid Tumor
Interventions: LDE225, Wafarin, Bupropion; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 13
States / cities: Duarte, California • Kansas City, Kansas • Boston, Massachusetts + 9 more

Conditions: Major Depression, Dysthymia, Depression NOS
Interventions: escitalopram + bupropion; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions: smoking cessation intervention, bupropion hydrochloride, gene expression analysis, polymerase chain reaction, counseling intervention, educational intervention, psychosocial assessment and care; Behavioral · Drug · Genetic + 2 more
Lead sponsor: Lisa Sanderson Cox, PhD; Other
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Kansas City, Kansas • Kansas City, Missouri

Conditions: Chronic Kidney Diseases, Deficiency, Vitamin D
Interventions: Cholecalciferol; Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Aurora, Colorado • Pittsburgh, Pennsylvania

Conditions: Depression, Major Depressive Disorder
Interventions: AXS-05, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 43
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 39 more

Conditions: Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions: bupropion hydrochloride, placebo; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy Volunteers
Interventions: BMS-986419, Caffeine, Bupropion, Flurbiprofen, Omeprazole, Midazolam, Fexofenadine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder, Schizophrenia
Interventions: Transdermal Nicotine Patch, 21 mg transdermal nicotine, placebo patch; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Major Depressive Disorder, Treatment Resistant Depression, Depression
Interventions: AXS-05 (dextromethorphan and bupropion) oral tablets; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 51
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 46 more

Conditions: Amphetamine-Related Disorders
Interventions: Bupropion; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 5
States / cities: Costa Mesa, California • San Diego, California • Honolulu, Hawaii + 2 more

Conditions: Loss-of-control Eating, Obesity/Overweight
Interventions: Naltrexone and Bupropion medication, Behavioral Weight Loss, Placebo; Drug · Behavioral · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Tobacco Dependence
Interventions: Bupropion; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 13 Years to 17 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pregnancy, Obesity, Overweight
Interventions: No Intervention; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 15 Years to 50 Years · Female only
Enrollment: 2,701 participants
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Princeton, New Jersey

Conditions: Smoking Cessation, Schizophrenia
Interventions: Combination Bupropion + NRTs, Extended Treatment, Home Visits & Calls, Monotherapy; Drug · Other
Lead sponsor: Brentwood Biomedical Research Institute; Other
Eligibility: 21 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Tobacco Use Disorder
Interventions: Pharmacotherapies for Smoking Cessation; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 20 Years to 65 Years
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tobacco Use Disorder
Interventions: nicotine transdermal system, bupropion, Medication Management, Mayo Counseling, placebo patch, placebo bupropion; Drug · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Drug Drug Interaction
Interventions: EPX-100, Itraconazole, Phenytoin, Omeprazole, Midazolam, Bupropion; Drug
Lead sponsor: Epygenix; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Cannabis Use Disorder, Stimulant Use Disorder, Opioid Use Disorder, Tobacco Use Disorder, Alcohol Use Disorder, Sedative, Hypnotic, or Anxiolytic Use Disorders
Interventions: Emotional Brain Training, Standard addiction counseling and medical therapy; Behavioral · Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Bernardino, California

Conditions: End Stage Renal Disease, Fatigue
Interventions: Bupropion Hydrochloride 150 MG; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 25 Years to 74 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Orgasmic Disorder
Interventions: Wellbutrin XL; Drug
Lead sponsor: Segraves, R., T., M.D., Ph.D.; Other
Eligibility: 20 Years to 50 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obesity
Interventions: naltrexone and bupropion SR; Drug
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 7
States / cities: San Diego, California • Augusta, Georgia • Lexington, Kentucky + 4 more

Conditions: Major Depression, End Stage Renal Disease
Interventions: Fluoxetine, Bupropion; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 30 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Smoking Cessation
Interventions: varenicline (CP-526,555); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,005 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 15
States / cities: Palo Alto, California • San Diego, California • Denver, Colorado + 12 more

Search by objective public record fields.

Bupropion and Restless Legs Syndrome

Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients

Are Two Antidepressants a Good Initial Treatment for Depression?

Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking

Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease

A Trial of AXS-05 in Patients With Major Depressive Disorder

Bupropion in Helping Adults Stop Smoking

A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants

Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

Open-Label Safety Study of AXS-05 in Subjects With Depression

Bupropion for the Treatment of Methamphetamine Dependence - 1

Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)

Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking

A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy

Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment

Bupropion as an Adjunct to the Nicotine Patch Plus CBT

Comparing Smoking Treatment Programs for Lighter Smokers - 1

Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants

Emotional Brain Training for Addiction Medicine Treatment - A Pilot Study

Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis

Female Orgasmic Disorder (FOD) and Wellbutrin XL

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

Bupropion for Depression in ESRD Patients on Hemodialysis

A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation